Indications for ABILIFY ORAL SOLUTION:

Acute and maintenance treatment of manic or mixed episodes in bipolar disorder as monotherapy; or as an
adjunct to lithium or valproate. Adjunct to antidepressants for major depressive disorder. Irritability associated
with autistic disorder.

Adult Dose for ABILIFY ORAL SOLUTION:

Tabs and soln may be interchanged on a mgtomg basis up to 25mg; 30mg as tablet is equivalent to 25mg oral
soln. Discmelt: Dissolve on tongue; take without liquids. Bipolar disorder: initially 15mg once daily; may
increase to max 30mg/day; maintenance: 15mg/day or 30mg/day (see literature for duration of therapy). Adjunct
to major depressive disorder: initially 25mg/day; may adjust by 5mg/day increments at intervals of 1 week;
usual range: 215mg/day. Reduce aripiprazole dose by at least with CYP3A4 inhibitors or CYP2D6 inhibitors.
Double aripiprazole dose (max 30mg/day) with CYP3A4 inducers. Adjust dose to normal range when these drugs
are withdrawn.

Children's Dose for ABILIFY ORAL SOLUTION:

<10yrs: not recommended. 1017yrs: Bipolar disorder: initially 2mg/day, then increase to 5mg/day after 2 days,
then increase to target dose of 10mg/day after 2 days. Subsequent dose increases may be adjusted by increments
of 5mg/day; max 30mg/day. Maintenance: continue at lowest dose to maintain remission; see literature.
Irritability w. autistic disorder: 617yrs: initially 2mg/day, then increase to 5mg/day; adjust dose by 5mg/day at
1 week intervals; usual range 515mg/day.

Warnings/Precautions:
Cardio- or cerebrovascular disease. Risk of hypotension, aspiration pneumonia, seizures, or diabetes (do baseline
fasting blood sugar). Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few
months of treatment; discontinue if WBCs decline. Exposure to extreme heat. Dehydration. Reevaluate
periodically. Monitor for hyperglycemia. Exclude neuroleptic malignant syndrome if fever occurs. Suicidal
tendencies. Write for smallest practical amount. Elderly (not for dementia-related psychosis). Labor & delivery.
Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester
pregnancy). Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:
Avoid alcohol. Caution with other centrally-acting drugs. Potentiates antihypertensives. Levels may be reduced
by CYP3A4 inducers (eg, carbamazepine). Levels may be increased by CYP3A4 inhibitors (eg, ketoconazole) or
CYP2D6 inhibitors (eg, quinidine, fluoxetine, paroxetine). Caution with drugs that interfere with temperature
regulation (eg, anticholinergics).

Adverse Reactions:
Headache, anxiety, insomnia, GI upset, somnolence, fatigue, akathisia, orthostatic hypotension, asthenia, blurred
vision, tremor, pyrexia, salivary hypersecretion, neuroleptic malignant syndrome, tardive dyskinesia, weight gain,
dyslipidemia, others. Inj: local reactions.

How Supplied:
Tabs 2mg30; 5mg, 10mg, 15mg, 20mg, 30mg30, 100; Oral soln (w. dosing cup)150mL; Discmelt30;
Single use vials1